for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Omeros Corporation

OMER.OQ

Latest Trade

13.70USD

Change

0.20(+1.48%)

Volume

109,085

Today's Range

13.30

 - 

13.82

52 Week Range

12.52

 - 

20.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Omeros Announces Proposed Public Offering Of Common Stock

Dec 4 (Reuters) - Omeros Corp <OMER.O>::OMEROS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.

Omeros Reports Third Quarter 2019 Financial Results

Nov 12 (Reuters) - Omeros Corp <OMER.O>::ORATION REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.33.Q3 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.Q3 REVENUE $29.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $27.2 MILLION.

Omeros Q2 Loss Per Share $0.29

Aug 8 (Reuters) - Omeros Corp <OMER.O>::ORATION REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.29.Q2 EARNINGS PER SHARE ESTIMATE $-0.44 -- REFINITIV IBES DATA.OMIDRIA REVENUES FOR 2Q 2019 WERE A RECORD HIGH AT $26.8 MILLION VERSUS $21.8 MILLION IN 1Q 2019.INVENTORY ON HAND AT WHOLESALERS AT JUNE 30, 2019 REMAINED CONSISTENT WITH HISTORICAL NORMS.

Omeros And Lonza Enter Long-Term Manufacturing Agreement For Commercial Supply Of Narsoplimab

July 31 (Reuters) - Omeros Corp <OMER.O>::OMEROS AND LONZA ENTER LONG-TERM MANUFACTURING AGREEMENT FOR COMMERCIAL SUPPLY OF NARSOPLIMAB.OMEROS CORP - OMEROS AND LONZA HAVE SUCCESSFULLY PARTNERED UNDER A MULTI-YEAR MANUFACTURING AGREEMENT FOR CLINICAL SUPPLY OF NARSOPLIMAB.OMEROS CORP - NEW MULTI-YEAR AGREEMENT SECURES A SOURCE OF COMMERCIAL QUANTITIES OF NARSOPLIMAB FOR USE FOLLOWING ANTICIPATED REGULATORY APPROVALS.OMEROS CORP - LONG-TERM MANUFACTURING AGREEMENT FOR COMMERCIAL PRODUCTION OF NARSOPLIMAB.

D. E. Shaw & Co Reports 5.0% Passive Stake In Omeros Corp

May 10 (Reuters) - D. E. Shaw & Co, L.P.: :D. E. SHAW & CO, L.P. REPORTS 5.0% PASSIVE STAKE IN OMEROS CORP AS OF APRIL 30 - SEC FILING.

D. E. Shaw & Co Reports 5.1 Percent Passive Stake In Omeros Corp As Of Feb 26, 2019

March 8 (Reuters) - Omeros Corp <OMER.O>::D. E. SHAW & CO REPORTS A PASSIVE STAKE OF 5.1 PERCENT IN OMEROS CORP AS OF FEB 26, 2019 - SEC FILING.

Omeros Reports Q4 Loss Per Share Of $0.48

March 1 (Reuters) - Omeros Corp <OMER.O>::ORATION REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.48.Q4 EARNINGS PER SHARE ESTIMATE $-0.81 -- REFINITIV IBES DATA.Q4 REVENUE $22 MILLION.Q4 REVENUE ESTIMATE $16.7 MILLION -- REFINITIV IBES DATA.AT DECEMBER 31, 2018, COMPANY HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AVAILABLE FOR OPERATIONS OF $60.5 MILLION.

Omeros Corp Streamlines Path To BLA For OMS721 Following Meeting With FDA

Feb 14 (Reuters) - Omeros Corp <OMER.O>::OMEROS CORPORATION STREAMLINES PATH TO BIOLOGICS LICENSE APPLICATION FOR OMS721 IN HSCT-TMA FOLLOWING MEETING WITH FDA.OMEROS CORP - HAS STREAMLINED REQUIRED WORK AND FURTHER ADVANCED ITS PREPARATIONS FOR ITS BIOLOGICS LICENSE APPLICATION FOR OMS721.OMEROS CORP - PATIENT DATA FROM EXISTING SINGLE-ARM STUDY WILL FORM BASIS FOR BLA; NO HISTORICAL CONTROL REQUIRED.OMEROS - PLANS TO MEET EUROPEAN REGULATORS, EXPECTS TO HARMONIZE MARKETING AUTHORIZATION APPLICATION FOR OMS721 IN HSCT-TMA IN EUROPE WITH U.S. BLA.OMEROS CORP - ENROLLING OMS721 PHASE 3 CLINICAL TRIALS FOR IMMUNOGLOBULIN A NEPHROPATHY & ATYPICAL HEMOLYTIC UREMIC SYNDROME.

Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy

Jan 17 (Reuters) - Omeros Corp <OMER.O>::OMEROS FINALIZES WITH FDA CLINICAL PLAN FOR OMS721 APPROVAL IN IGA NEPHROPATHY.OMEROS CORP - ADDITIONAL POSITIVE DATA REPORTED FROM SECOND COHORT IN PHASE 2 TRIAL--.OMEROS CORP - ADDITIONAL POSITIVE DATA REPORTED FROM SECOND COHORT IN PHASE 2 TRIAL.OMEROS - OMS721 CONTINUES TO BE WELL TOLERATED AND NO SAFETY CONCERNS HAVE BEEN OBSERVED.OMEROS CORP - DURING FDA MEETING, IT WAS CONFIRMED THAT PHASE 3 TRIAL'S PRIMARY ENDPOINT OF ASSESSMENT OF PROTEINURIA WILL BE EXTENDED TO 36 WEEKS.

Omeros Corp Reports Preliminary Total And Omidria Q4 Revenues Of About $22 Mln

Jan 14 (Reuters) - Omeros Corp <OMER.O>::ORATION ANNOUNCES RECORD HIGH QUARTERLY REVENUE RESULTS FOR THE FOURTH QUARTER 2018.PRELIMINARY TOTAL AND OMIDRIA REVENUES FOR Q4 OF 2018 ARE EXPECTED TO BE A RECORD HIGH AT APPROXIMATELY $22.0 MILLION.DOES NOT CURRENTLY INTEND IN FUTURE TO MAKE PUBLIC PRELIMINARY SALES REVENUES ON A ROUTINE BASIS.Q4 PRELIMINARY ANNUALIZED RUN RATE OF WEEKLY NET SALES IN DECEMBER WAS ABOUT $100 MILLION.Q4 REVENUE VIEW $13.9 MILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up